# Randomised Trial in Waldenstrom's Macroglobulinaemia

> **NCT01592981** · PHASE2 · COMPLETED · sponsor: **University College, London** · enrollment: 60 (actual)

## Conditions studied

- Waldenstrom's Macroglobulinaemia

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Rituximab
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT01592981
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2017-03
- **Final completion:** 2020-08-02
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01592981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01592981, "Randomised Trial in Waldenstrom's Macroglobulinaemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01592981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*